Cargando…

Breeze: an integrated quality control and data analysis application for high-throughput drug screening

SUMMARY: High-throughput screening (HTS) enables systematic testing of thousands of chemical compounds for potential use as investigational and therapeutic agents. HTS experiments are often conducted in multi-well plates that inherently bear technical and experimental sources of error. Thus, HTS dat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Potdar, Swapnil, Ianevski, Aleksandr, Mpindi, John-Patrick, Bychkov, Dmitrii, Fiere, Clément, Ianevski, Philipp, Yadav, Bhagwan, Wennerberg, Krister, Aittokallio, Tero, Kallioniemi, Olli, Saarela, Jani, Östling, Päivi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Applications Notes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267830/ https://www.ncbi.nlm.nih.gov/pubmed/32119072 http://dx.doi.org/10.1093/bioinformatics/btaa138

Ejemplares similares

Breeze 2.0: an interactive web-tool for visual analysis and comparison of drug response data
por: Potdar, Swapnil, et al.
Publicado: (2023)

Impact of normalization methods on high-throughput screening data with high hit rates and drug testing with dose–response data
por: Mpindi, John-Patrick, et al.
Publicado: (2015)

SynergyFinder: a web application for analyzing drug combination dose–response matrix data
por: Ianevski, Aleksandr, et al.
Publicado: (2017)

TIMMA-R: an R package for predicting synergistic multi-targeted drug combinations in cancer cell lines or patient-derived samples
por: He, Liye, et al.
Publicado: (2015)

High-throughput compound screening identifies navitoclax combined with irradiation as a candidate therapy for HPV-negative head and neck squamous cell carcinoma
por: Tuomainen, Katja, et al.
Publicado: (2021)

Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model
por: Yadav, Bhagwan, et al.
Publicado: (2015)

Corrigendum to “Searching for drug synergy in complex dose–response landscapes using an interaction potency model” [Comput. Struct. Biotechnol. J. 13 (2015) 504–513]
por: Yadav, Bhagwan, et al.
Publicado: (2017)

SynergyFinder 2.0: visual analytics of multi-drug combination synergies
por: Ianevski, Aleksandr, et al.
Publicado: (2020)

Fully-automated and ultra-fast cell-type identification using specific marker combinations from single-cell transcriptomic data
por: Ianevski, Aleksandr, et al.
Publicado: (2022)

SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples
por: Ianevski, Aleksandr, et al.
Publicado: (2022)

SynergyFinder: a web application for analyzing drug combination dose–response matrix data
por: Ianevski, Aleksandr, et al.
Publicado: (2020)

SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy
por: Ianevski, Aleksandr, et al.
Publicado: (2020)

Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic Leukemia
por: Hohtari, Helena, et al.
Publicado: (2022)

Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
por: Malani, Disha, et al.
Publicado: (2022)

Target Inhibition Networks: Predicting Selective Combinations of Druggable Targets to Block Cancer Survival Pathways
por: Tang, Jing, et al.
Publicado: (2013)

Improved detection of differentially represented DNA barcodes for high‐throughput clonal phenomics
por: Akimov, Yevhen, et al.
Publicado: (2020)

Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells
por: Gautam, Prson, et al.
Publicado: (2016)

From drug response profiling to target addiction scoring in cancer cell models
por: Yadav, Bhagwan, et al.
Publicado: (2015)

Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies
por: Yadav, Bhagwan, et al.
Publicado: (2014)

What is synergy? The Saariselkä agreement revisited
por: Tang, Jing, et al.
Publicado: (2015)

Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma
por: Murumägi, Astrid, et al.
Publicado: (2022)

Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer
por: Tang, Jing, et al.
Publicado: (2019)

A normalized drug response metric improves accuracy and consistency of anticancer drug sensitivity quantification in cell-based screening
por: Gupta, Abhishekh, et al.
Publicado: (2020)

Novel Screening Method Identifies PI3Kα, mTOR, and IGF1R as Key Kinases Regulating Cardiomyocyte Survival
por: Elmadani, Manar, et al.
Publicado: (2019)

Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer
por: Kangaspeska, Sara, et al.
Publicado: (2016)

High miR-30 Expression Associates with Improved Breast Cancer Patient Survival and Treatment Outcome
por: Jamshidi, Maral, et al.
Publicado: (2021)

High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma
por: Kohtamäki, Laura, et al.
Publicado: (2021)

Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach
por: Ali, Mehreen, et al.
Publicado: (2018)

Patient-tailored design for selective co-inhibition of leukemic cell subpopulations
por: Ianevski, Aleksandr, et al.
Publicado: (2021)

EnrichIntersect: an R package for custom set enrichment analysis and interactive visualization of intersecting sets
por: Zhao, Zhi, et al.
Publicado: (2022)

Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas
por: Brodin, Bertha A., et al.
Publicado: (2019)

Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia
por: White, Brian S., et al.
Publicado: (2021)

Comprehensive data-driven analysis of the impact of chemoinformatic structure on the genome-wide biological response profiles of cancer cells to 1159 drugs
por: Khan, Suleiman A, et al.
Publicado: (2012)

Systematic identification of feature combinations for predicting drug response with Bayesian multi-view multi-task linear regression
por: Ammad-ud-din, Muhammad, et al.
Publicado: (2017)

ePCR: an R-package for survival and time-to-event prediction in advanced prostate cancer, applied to real-world patient cohorts
por: Laajala, Teemu D, et al.
Publicado: (2018)

P1228: GENOME-WIDE CRISPR-CAS9 SCREENING IDENTIFIES THERAPEUTIC TARGETS FOR MATURE T-CELL MALIGNANCIES
por: Timonen, Sanna, et al.
Publicado: (2023)

Breathing: old and fresh breezes in Orthodontics
por: Artese, Flavia
Publicado: (2020)

Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses
por: White, Judith M., et al.
Publicado: (2021)

Seed-effect modeling improves the consistency of genome-wide loss-of-function screens and identifies synthetic lethal vulnerabilities in cancer cells
por: Jaiswal, Alok, et al.
Publicado: (2017)

High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion
por: Lehtinen, Laura, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_12f7bivvq1kiekb6l8i6ge8jed